Kết quả tìm kiếm - Mark Kirschbaum

Tinh chỉnh kết quả
  1. 1
    SIRT1 activation enhances HDAC inhibition-mediated upregulation of GADD45G by repressing the binding of NF-κB/STAT3 complex to its promoter in malignant lymphoid cells

    SIRT1 activation enhances HDAC inhibition-mediated upregulation of GADD45G by repressing the binding of NF-κB/STAT3 complex to its promoter in malignant lymphoid cells Bằng A Scuto, Mark Kirschbaum, Ralf Buettner, Maciej Kujawski, J Cermák, Peter Atadja, Richard Jove

    Được phát hành 2013
    lấy văn bản lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  2. 2
    A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: a California Cancer Consortium Study

    A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: a... Bằng Mark Kirschbaum, Kenneth A. Foon, Paul Frankel, Christopher Ruel, Bernadette Pulone, Joseph M. Tuscano, Edward M. Newman

    Được phát hành 2013
    lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  3. 3
    A phase 2 study of vorinostat for treatment of relapsed or refractory Hodgkin lymphoma: Southwest Oncology Group Study S0517

    A phase 2 study of vorinostat for treatment of relapsed or refractory Hodgkin lymphoma: Southwest Oncology Group Study S0517 Bằng Mark Kirschbaum, Bryan Goldman, Jasmine Zain, James R. Cook, Lisa M. Rimsza, Stephen J. Forman, Richard I. Fisher

    Được phát hành 2011
    lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  4. 4
    HDAC inhibitor reduces cytokine storm and facilitates induction of chimerism that reverses lupus in anti-CD3 conditioning regimen

    HDAC inhibitor reduces cytokine storm and facilitates induction of chimerism that reverses lupus in anti-CD3 conditioning regimen Bằng Nainong Li, Dongchang Zhao, Mark Kirschbaum, Chunyan Zhang, Chia-Lei Lin, Иван Тодоров, Fouad Kandeel, Stephen J. Forman, Defu Zeng

    Được phát hành 2008
    lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  5. 5
    Combining Histone Deacetylase Inhibitor Vorinostat with Aurora Kinase Inhibitors Enhances Lymphoma Cell Killing with Repression of c-Myc, hTERT, and microRNA Levels

    Combining Histone Deacetylase Inhibitor Vorinostat with Aurora Kinase Inhibitors Enhances Lymphoma Cell Killing with Repression of c-Myc, hTERT, and microRNA Levels Bằng Leo Kretzner, Anna Scuto, Pamela M. Dino, Claudia Kowolik, Jun Wu, Patrick Ventura, Richard Jove, Stephen J. Forman, Yun Yen, Mark Kirschbaum

    Được phát hành 2011
    lấy văn bản lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  6. 6
    The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph− acute lymphoblastic leukemia cells

    The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph− acute lymphoblastic leukemia cells Bằng Anna Scuto, Mark Kirschbaum, Claudia Kowolik, Leo Kretzner, Ágnes Juhász, Peter Atadja, Vinod Pullarkat, Ravi Bhatia, Stephen J. Forman, Yun Yen, Richard Jove

    Được phát hành 2008
    lấy văn bản lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  7. 7
    Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome

    Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome Bằng Eldad J. Dann, Rachel Bar‐Shalom, Ada Tamir, Nissim Haim, Menachem Ben‐Shachar, Irit Avivi, Tzila Zuckerman, Mark Kirschbaum, Odelia Goor, Diana Libster, Jacob M. Rowe, Ron Epelbaum

    Được phát hành 2006
    lấy văn bản lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  8. 8
    A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma

    A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma Bằng Robert Chen, Paul Frankel, Leslie Popplewell, Tanya Siddiqi, Nora Ruel, A Rotter, Sandra H. Thomas, Michelle Mott, Nitya Nathwani, Myo Htut, AP Nademanee, Stephen J. Forman, Mark Kirschbaum

    Được phát hành 2015
    lấy văn bản lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  9. 9
    Sorafenib inhibits signal transducer and activator of transcription 3 signaling associated with growth arrest and apoptosis of medulloblastomas

    Sorafenib inhibits signal transducer and activator of transcription 3 signaling associated with growth arrest and apoptosis of medulloblastomas Bằng Fan Yang, Timothy Van Meter, Ralf Buettner, Michael Hedvat, Wei Liang, Claudia Kowolik, Nilesh Mepani, Janni Mirosevich, Sangkil Nam, Mike Y. Chen, Gary Tye, Mark Kirschbaum, Richard Jove

    Được phát hành 2008
    lấy văn bản lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  10. 10
    A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome

    A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome Bằng Mark Kirschbaum, Ivana Gojo, Stuart L. Goldberg, Christopher Bredeson, Lisa Kujawski, Allen S. Yang, Peter Marks, Paul Frankel, Xing Sun, Alessandra Tosolini, Joseph Eid, Gregory M. Lubiniecki, Jean–Pierre J. Issa

    Được phát hành 2014
    lấy văn bản lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  11. 11
    Nonmyeloablative Stem Cell Transplantation and Cell Therapy as an Alternative to Conventional Bone Marrow Transplantation With Lethal Cytoreduction for the Treatment of Malignant and Nonmalignant Hematologic Diseases

    Nonmyeloablative Stem Cell Transplantation and Cell Therapy as an Alternative to Conventional Bone Marrow Transplantation With Lethal Cytoreduction for the Treatment of Malignant a... Bằng Shimon Slavin, Arnon Nagler, E Naparstek, Y. Kapelushnik, Memet Aker, Gabriel Cividalli, Gàbor Varadi, Mark Kirschbaum, Aliza Ackerstein, Simcha Samuel, Avraham Amar, Chaim Brautbar, Ofira Ben‐Tal, A Eldor, Reuven Or

    Được phát hành 1998
    lấy văn bản lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  12. 12
    Nonmyeloablative Stem Cell Transplantation and Cell Therapy as an Alternative to Conventional Bone Marrow Transplantation With Lethal Cytoreduction for the Treatment of Malignant and Nonmalignant Hematologic Diseases

    Nonmyeloablative Stem Cell Transplantation and Cell Therapy as an Alternative to Conventional Bone Marrow Transplantation With Lethal Cytoreduction for the Treatment of Malignant a... Bằng Shimon Slavin, Arnon Nagler, E Naparstek, Y. Kapelushnik, Memet Aker, Gabriel Cividalli, Gàbor Varadi, Mark Kirschbaum, Aliza Ackerstein, Simcha Samuel, Avraham Amar, Chaim Brautbar, Ofira Ben‐Tal, A Eldor, Reuven Or

    Được phát hành 1998
    lấy văn bản lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  13. 13
    Phase II Study of Vorinostat for Treatment of Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma

    Phase II Study of Vorinostat for Treatment of Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma Bằng Mark Kirschbaum, Paul Frankel, Leslie Popplewell, Jasmine Zain, Maria Delioukina, Vinod Pullarkat, Deron Matsuoka, Bernadette Pulone, A Rotter, Igor Espinoza‐Delgado, Auayporn Nademanee, Stephen J. Forman, David R. Gandara, Edward M. Newman

    Được phát hành 2011
    lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  14. 14
    A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma

    A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma Bằng Joseph M. Tuscano, Emanual Maverakis, Susan Groshen, Denice Tsao‐Wei, Guillaume Luxardi, Alexander A. Merleev, Anne Beaven, John F. DiPersio, Leslie Popplewell, Robert Chen, Mark Kirschbaum, Mark A. Schroeder, Edward M. Newman

    Được phát hành 2019
    lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  15. 15
    Immune regulatory effects of panobinostat in patients with Hodgkin lymphoma through modulation of serum cytokine levels and T-cell PD1 expression

    Immune regulatory effects of panobinostat in patients with Hodgkin lymphoma through modulation of serum cytokine levels and T-cell PD1 expression Bằng Yasuhiro Oki, Daniela Buglio, J. Zhang, Y Ying, Shouhao Zhou, Anna Sureda, Dina Ben‐Yehuda, Pier Luigi Zinzani, H. Miles Prince, Simon J. Harrison, Mark Kirschbaum, Patrick B. Johnston, Angela Shen, Bastian von Tresckow, Anas Younes

    Được phát hành 2014
    lấy văn bản lấy văn bản
    Carta
    Lưu vào danh sách
    Đã lưu trong:
  16. 16
    Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma

    Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma Bằng Richard Piekarz, Robin Frye, H. Miles Prince, Mark Kirschbaum, Jasmine Zain, Steven L. Allen, Elaine S. Jaffe, Alexander Ling, Maria L. Turner, Cody J. Peer, William D. Figg, Seth M. Steinberg, Sonali M. Smith, David Joske, Ian A. Lewis, Laura F. Hutchins, Michael Craig, Antonio Tito Fojo, James R. Wright, Susan E. Bates

    Được phát hành 2011
    lấy văn bản lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  17. 17
    Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma

    Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma Bằng Richard Piekarz, Robin Frye, Maria L. Turner, John J. Wright, Steven L. Allen, Mark Kirschbaum, Jasmine Zain, H. Miles Prince, John P. Leonard, Larisa J. Geskin, Craig B. Reeder, David Joske, William D. Figg, Erin R. Gardner, Seth M. Steinberg, Elaine S. Jaffe, Maryalice Stetler‐Stevenson, Stephen Lade, Antonio Tito Fojo, Susan E. Bates

    Được phát hành 2009
    lấy văn bản lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  18. 18
    Efficacy of mycophenolate mofetil in the treatment of chronic graft-versus-host disease

    Efficacy of mycophenolate mofetil in the treatment of chronic graft-versus-host disease Bằng Francisco López, Pablo Parker, Auayporn Nademanee, Roberto Rodríguez, Zaid Al‐Kadhimi, Ravi Bhatia, Sandra Cohen, Peter Falk, Henry C. Fung, Mark Kirschbaum, Amrita Krishnan, Neil Kogut, Arturo Molina, Ryotaro Nakamura, Margaret O’Donnell, Leslie Popplewell, Vinod Pullarkat, Joseph Rosenthal, Firoozeh Sahebi, Eileen Smith, David S. Snyder, George Somlo, Ricardo Spielberger, Anthony S. Stein, Robert Sweetman, Jasmine Zain, Stephen J. Forman

    Được phát hành 2005
    lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  19. 19
    Phase II Study of the Oral MEK Inhibitor Selumetinib in Advanced Acute Myelogenous Leukemia: A University of Chicago Phase II Consortium Trial

    Phase II Study of the Oral MEK Inhibitor Selumetinib in Advanced Acute Myelogenous Leukemia: A University of Chicago Phase II Consortium Trial Bằng Nitin Jain, Emily Curran, Neil M. Iyengar, Ernesto Díaz-Flores, Rangesh Kunnavakkam, Leslie Popplewell, Mark Kirschbaum, Theodore Karrison, Harry P. Erba, Margaret Green, Xavier Poiré, Greg Koval, Kevin Shannon, Poluru L. Reddy, Loren Joseph, Ehab Atallah, Philip A. Dy, Sachdev Thomas, Scott E. Smith, L. Austin Doyle, Walter M. Stadler, Richard A. Larson, Wendy Stock, Olatoyosi Odenike

    Được phát hành 2013
    lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  20. 20
    A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma

    A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in pati... Bằng Auayporn Nademanee, Stephen J. Forman, Arturo Molina, Henry C. Fung, David Smith, Andy Dagis, Cheuk Kwok, Dave Yamauchi, Anne-Line Anderson, Peter Falk, Amrita Krishnan, Mark Kirschbaum, Neil Kogut, Ryotaro Nakamura, Margaret O’Donnell, Pablo Parker, Leslie Popplewell, Vinod Pullarkat, Roberto Rodríguez, Firoozeh Sahebi, Eileen Smith, David S. Snyder, Anthony S. Stein, Ricardo Spielberger, Jasmine Zain, Christine A. White, Andrew Raubitschek

    Được phát hành 2005
    lấy văn bản lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:

Công cụ tìm kiếm: